TY - JOUR
T1 - Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy
AU - Omura, Minami
AU - Kosaka, Takeo
AU - Kobayashi, Hiroaki
AU - Shigeta, Keisuke
AU - Matsumoto, Kazuhiro
AU - Hara, Satoshi
AU - Kikuchi, Eiji
AU - Mikami, Shuji
AU - Saya, Hideyuki
AU - Sato, Yasufumi
AU - Oya, Mototsugu
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/5
Y1 - 2024/5
N2 - Background and purpose: Neoadjuvant chemotherapy (NAC) is a well-established standard practice in invasive bladder cancer (BCa), however patient selection remains challenging. High expression of vasohibin-1 (VASH1), an endogenous regulator of angiogenesis, has been reported in high-grade and advanced BCa; however, its prognostic value for chemotherapy outcomes remains unexplored. In this study, we sought to identify biomarkers of chemotherapy response focusing on the relationship between angiogenesis and tissue hypoxia. Methods: Forty Japanese patients with BCa who underwent NAC and radical cystectomy were included in the present analysis. We compared the immunohistochemical expression of CD34, VASH1, and carbonic anhydrase 9 (CA9) between patients who achieved tumor clearance at operation (ypT0) and those with residual disease after cystectomy. Results: There were 19 patients in the ypT0 group, while the remaining 21 patients had residual tumors at operation. Patients in the ypT0 group had high microvessel density (p = 0.031), high VASH1 density (p < 0.001), and stronger CA9 staining (p = 0.046) than their counterparts. Multivariate analysis identified microvessel and VASH1 density as independent predictive factors for pathological ypT0 disease (p = 0.043 and 0.002, respectively). The 5-year recurrence-free survival rate was higher in the high VASH1 density group than in the low VASH1 density group (66.3% vs. 33.3%, p = 0.036). Conclusion: VASH1 density is a potential therapeutic biomarker for chemotherapy response in BCa.
AB - Background and purpose: Neoadjuvant chemotherapy (NAC) is a well-established standard practice in invasive bladder cancer (BCa), however patient selection remains challenging. High expression of vasohibin-1 (VASH1), an endogenous regulator of angiogenesis, has been reported in high-grade and advanced BCa; however, its prognostic value for chemotherapy outcomes remains unexplored. In this study, we sought to identify biomarkers of chemotherapy response focusing on the relationship between angiogenesis and tissue hypoxia. Methods: Forty Japanese patients with BCa who underwent NAC and radical cystectomy were included in the present analysis. We compared the immunohistochemical expression of CD34, VASH1, and carbonic anhydrase 9 (CA9) between patients who achieved tumor clearance at operation (ypT0) and those with residual disease after cystectomy. Results: There were 19 patients in the ypT0 group, while the remaining 21 patients had residual tumors at operation. Patients in the ypT0 group had high microvessel density (p = 0.031), high VASH1 density (p < 0.001), and stronger CA9 staining (p = 0.046) than their counterparts. Multivariate analysis identified microvessel and VASH1 density as independent predictive factors for pathological ypT0 disease (p = 0.043 and 0.002, respectively). The 5-year recurrence-free survival rate was higher in the high VASH1 density group than in the low VASH1 density group (66.3% vs. 33.3%, p = 0.036). Conclusion: VASH1 density is a potential therapeutic biomarker for chemotherapy response in BCa.
KW - Angiogenesis
KW - Biomarkers
KW - Bladder cancer
KW - Chemotherapy
KW - Pathological outcome
UR - http://www.scopus.com/inward/record.url?scp=85185966765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85185966765&partnerID=8YFLogxK
U2 - 10.1245/s10434-024-15009-1
DO - 10.1245/s10434-024-15009-1
M3 - Article
C2 - 38376711
AN - SCOPUS:85185966765
SN - 1068-9265
VL - 31
SP - 2951
EP - 2958
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 5
ER -